Adalimumab
Adalimumab, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. In rheumatoid arthritis, adalimumab has a response rate similar to methotrexate, and in combination, it nearly doubles the response rate of methotrexate alone.Adalimumab
Trastuzumab
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin. Trastuzumab was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale price in the developing world is between 1,800 and 1,955 USD per 440 mg vial. In the United Kingdom a 150 mg vial costs the NHS 407.00 pounds.Trastuzumab
Bevacizumab
Bevacizumab, sold under the trade name Avastin, is medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age-related macular degeneration it is given by injection into the eye. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels. Bevacizumab was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.Bevacizumab
Rituximab
Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, idiopathic thrombocytopenic purpura, pemphigus vulgaris and myasthenia gravis. It is given by slow injection into a vein. Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab was approved for medical use in 1997. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale price in the developing world as of 2014 is US$148–496 per 100 mg.Rituximab
Alemutuzmab
Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade names Campath, MabCampath and Campath-1H, and in the treatment of multiple sclerosis as Lemtrada. It is also used in some conditioning regimens for bone marrow transplantation, kidney transplantation and islet cell transplantation. It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived.Alemutuzmab
People.
Luc-Alain Savoy
Chairman
/ PhD.
Dr Savoy is co-Founder and Chairman of BioXpress Therapeutics SA. Previously, he co-founded in 1991 M-Scan SA, a contract research organisation specializing in high level of bioproducts characterization, prior to selling it to SGS. He is currently Global Head of Biologics, at SGS Life Sciences.
Cori Gorman
Board member
/ PhD, MBA
Dr. Gorman is a Co-Founder of BioXpress. She currently serves as a Board member and brings over 30 years experience in the biotechnology industry, including six years as CEO/Chairman of BioXpress.
Igor Fisch
Founder
/ PhD.
Dr. Fisch is passionate and dedicated to scientific excellence. He has been instrumental in building Selexis and BioXpress Therapeutics SA into world-class leaders in cell line and biosimilars drug development. Cell lines that have been developed with Selexis’ technology are being used from discovery to late-phase clinical trials and for approved products. In 2016, BioProcess International named Dr. Fisch as the winner of the 2016 “Excellence in Leadership Award.” This honor was bestowed to Dr. Fisch as an outstanding leader who defines excellence and who has enabled more effective, less expensive bio therapeutic development and manufacturing.
Alexandra Richardson
Board member
/ PhD.
Dr. Richardson is a Director at BioXpress. She is currently head of business development for US-based Clayton Biotechnologies, Inc. and also serves as strategic business development advisor to several biotech companies in the US, Switzerland and Japan.
Gerrit Hagens
Board Director
/ PhD, MBA
Before being appointed Professor at the University of Applied Sciences HES-SO, Sion, Switzerland, Gerrit Hagens gained a strong manufacturing process development experience during during the last 20 years in the industry. In 2010 he joined BioXpress where he heads project management.
Sylvie Ryckebusch
Business Development Advisor
/ PhD.
Dr. Ryckebusch provides business development support to BioXpress. She has 20 years of business development experience and works with numerous biotechs in the US and Europe as founder of Octave Biotech Consulting. Sylvie held senior roles within business development and alliance management within Merck Serono following several years of strategic consultancy at McKinsey & Company.
Pipeline.
Trastuzumab
Adalimumab
Rituximab
Alemutuzmab
Bevacizumab
Partners.
Consulting partner: Geneva, Switzerland
https://www.arbbiotech.com
Manufacturing partner: Monthey, Switzerland
https://swissbiotechcenter.com
Research partner: Slon, Switzerland
https://www.hes-so.ch
Cell-line partner: Geneva, Switzerland
https://selexis.com
Analytics partner: Geneva, Switzerland
https://www.sgs.com
Consulting partner: Geneva, Switzerland
http://www.octavebiotech.com/About.
Biopharmaceuticals have revolutionized modern medicine and given new hope for those diagnosed with cancer and other devastating chronic diseases. Monoclonal antibodies remain the most advanced and effective therapeutics for such diseases to date. Biosimilars promise to make these cutting-edge drugs more accessible, offering to prolong and improve the lives of even a greater number of patients across the globe.
Here at BioXpress we create biosimilars of uncompromising quality. We develop in Switzerland and manufacture for distribution worldwide.
BioXpress was founded in Geneva by the industry leaders in cell-line development and analytical characterization and has built a team of experts in the development of biopharmaceuticals and biosimilars, their manufacturing, characterization, clinical and regulatory development. Our partnership with Selexis ensures highest standards in cell-line development, coupled with a collaboration with SGS for analytics, and priority access to laboratories and a CMO in Switzerland for optimal process development and GMP manufacturing so that the development of our biosimilars can be managed in a cost-effective and streamlined process.
Become a partner, explore the opportunities that our pipeline could bring to your company. Our industry veterans are here to support you from generating the optimal cell-line to the optimal regulatory development path and beyond. Contact us today. Because, together, we are stronger.
